The Changes of Biomarkers by Telmisartan and their Significance in Cardiovascular Outcomes: Design of a Trial of Telmisartan Prevention of Cardiovascular Diseases (ATTEMPT-CVD)

Hirofumi Soejima^1,2, Hisao Ogawa^1*, Osamu Yasud³, Shokei Kim-Mitsuyam⁴, Kunihiko Matsui⁵, Koichi Nod⁶, Megumi Yamamuro¹, Eiichiro Yamamoto¹, Keiichiro Kataok⁴, Hideaki Jinnouchi⁷ and Taiji Sekigami⁸

¹Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

²Health Care Center, Kumamoto University, Kumamoto, Japan

³Department of Cardiovascular Clinical and Translational Research, Kumamoto University, Kumamoto, Japan

⁴Department of Pharmacology and Molecular Therapeutics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

⁵Department of General Internal Medicine, Yamaguchi University, Ube, Japan

⁶Department of Cardiovascular Medicine, Saga University, Saga, Japan

⁷Diabetes Care Center, Jinnouchi Clinic, Kumamoto, Japan

⁸Department of Metabolism and Endocrine, Kumamoto Social Insurance General Hospital, Yatsushiro, Japan

^*Corresponding Author: Hisao Ogawa, Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Honjo, Kumamoto City, Japan, Tel: 81-96-373-5175, Fax: 81-96-362-3256 Email: